Press releases
- REGENXBIO to Participate in Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
- REGENXBIO Announces Lancet Publication of Phase I/IIa Study Evaluating ABBV-RGX-314 as a One-Time Gene Therapy for Wet AMD
- REGENXBIO to Participate in Cantor Fitzgerald's Virtual DMD and Other Dystrophy Days
- REGENXBIO to Participate in Upcoming Investor Conferences
- REGENXBIO Announces Pricing of Upsized Public Offering of Common Stock and Pre-funded Warrants
- REGENXBIO Announces Proposed Public Offering of Common Stock
- REGENXBIO ANNOUNCES NEW POSITIVE INITIAL EFFICACY DATA FROM AFFINITY DUCHENNE® TRIAL
- REGENXBIO to Host Webcast Event to Discuss New Interim Clinical Data from the Phase I/II AFFINITY DUCHENNE® Trial
- REGENXBIO Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights
- REGENXBIO to Host Conference Call on February 27 to Discuss Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights
More ▼
Key statistics
On Wednesday, Regenxbio Inc (RB0:DEU) closed at 14.90, 36.70% above the 52 week low of 10.90 set on Oct 31, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 14.80 |
---|---|
High | 14.90 |
Low | 14.50 |
Bid | 14.90 |
Offer | 15.00 |
Previous close | 14.70 |
Average volume | 0.00 |
---|---|
Shares outstanding | 49.04m |
Free float | 45.18m |
P/E (TTM) | -- |
Market cap | 786.65m USD |
EPS (TTM) | -6.03 USD |
Data delayed at least 15 minutes, as of Apr 24 2024.
More ▼